Abstract
Vascular smooth muscle cells (VSMCs) are highly phenotypically plastic, and loss of the contractile phenotype in VSMCs has been recognized at the early onset of the pathology of a variety of vascular diseases. However, the endogenous regulatory mechanism to maintain contractile phenotype in VSMCs remains elusive. Moreover, little has been known about the role of the mitochondrial bioenergetics in terms of VSMC homeostasis. Herein, we asked if glycoprotein COMP (Cartilage oligomeric matrix protein) is involved in mitochondrial bioenergetics and therefore regulates VSMCs homeostasis. By using fluorescence assay, subcellular western blot and liquid chromatography tandem mass spectrometry analysis, we found that extracellular matrix protein COMP unexpectedly localized within mitochondria. Further mitochondrial transplantation revealed that both mitochondrial and non-mitochondrial COMP maintained VSMC identity. Moreover, microarray analysis revealed that COMP deficiency impaired mitochondrial oxidative phosphorylation in VSMCs. Further study confirmed that COMP deficiency caused mitochondrial oxidative phosphorylation dysfunction accompanied by morphological abnormality. Moreover, the interactome of mitochondrial COMP revealed that COMP interacted with prohibitin 2, and COMP–prohibitin 2 interaction maintained mitochondrial homeostasis. Additionally, disruption of COMP–prohibitin 2 interaction caused VSMC dedifferentiation in vitro and enhanced the neointima formation post rat carotid artery injury in vivo. In conclusion, COMP–prohibitin 2 interaction in mitochondria plays an important role in maintaining the contractile phenotype of VSMCs by regulating mitochondrial oxidative phosphorylation. Maintaining the homeostasis of mitochondrial respiration through COMP–prohibitin 2 interaction may shed light on prevention of vascular disease.
Introduction
Vascular smooth muscle cells (VSMCs) are of high plasticity and can undergo reversible changes in phenotype in response to alterations in local environmental cues1. In mature blood vessels, VSMCs exhibit a “contractile” or “differentiated” phenotype characterized by the expression of contractile markers, including smooth muscle myosin heavy chain (SM-MHA), SM α-actin, SM-22 and calponin. However, under certain circumstances, VSMCs can undergo phenotype transition toward a non-contractile or dedifferentiated phenotype characterized by reduced expression of contractile markers and increased capacity for cell proliferation, migration, or secretion of various extracellular matrix (ECM) proteins and cytokines. Accumulating evidence has suggested that phenotypic transition of VSMCs occurs at the early onset of the pathology of several vascular diseases, including atherosclerosis, post-injury restenosis, vascular calcification and aortic aneurysms2–5. To date, compelling studies have identified the contribution of growth factors, mitogenic cytokines, reactive oxygen species, hypoxia, stretch and injury to cell dedifferentiation6–9. Recent studies have also revealed the importance of CArG-SRF-myocardin-dependent transcriptional mechanisms and epigenetic controls in the regulation of VSMC differentiation10. Nevertheless, how quiescent VSMCs maintain the differentiated state upon environmental cues is much less understood.
Mitochondria are the energy powerhouses for ATP production and are particularly abundant in muscle cells, including human VSMCs11. Until recently, little has been known about the role of the bioenergetics of VSMC mitochondria in terms of vascular function and disease. The bioenergetics of human VSMCs via mitochondrial metabolism mainly relies on oxygen-consuming mitochondrial oxidative phosphorylation (OXPHOS) due to high efficiency of ATP production, whereas glycolysis is also involved12,13. It has become increasingly evident that under certain disease conditions, there is damage to the mitochondria that limits their ability to generate ATP via oxidative phosphorylation, leading to mitochondrial dysfunction. Subsequently, mitochondrial dysfunction causes the overproduction of reactive oxygen species (ROS), mitochondrial DNA damage, aberrant mitochondrial dynamics and disturbed calcium homeostasis, ultimately contributing to cardiovascular diseases such as atherosclerosis14–17. A few studies have shown that during aortic VSMC dedifferentiation induced by serum or PDGF-BB, mitochondria undergo metabolic reprogramming and decreased ATP production18. Moreover, complex I dysfunction underlies the oxidative phosphorylation-to-glycolysis switch in pulmonary hypertensive smooth muscle cells19. However, the definitive role of mitochondrial respiration in the VSMC phenotypic transition and the underlying mechanism have been little studied.
Cartilage oligomeric matrix protein (COMP), a 524-kDa pentameric noncollagenous glycoprotein, is an extracellular matrix protein found in both the musculoskeletal and cardiovascular systems. Our recent studies have demonstrated that COMP plays key roles in the maintenance of VSMC homeostasis. COMP maintains the contractile phenotype of VSMCs via integrin α7β1 and prevents osteochondrogenic transdifferentiation of VSMCs by directly binding to BMP-2, which inhibits post-injury neointima formation and vascular calcification respectively20,21. We recently also demonstrated that COMP negatively regulates atherosclerosis and lesional calcification formation via direct interaction with integrin β322. In the current study, we identified an unexpected intracellular localization of COMP and a role of the COMP–prohibitin 2 interaction in the maintenance of mitochondrial homeostasis and the regulation of VSMC phenotype switching. The prohibitins are highly conserved proteins in eukaryotic cells that are present in multiple cellular compartments including mitochondrion, cytoplasm and nucleus of a variety of cells23,24. In the mitochondrial inner membrane, prohibitin 1 and prohibitin 2 form a ring-like structure, thus maintains mitochondrial genome stability, mitochondrial dynamics and promotes mitochondrial respiratory chain complex assembling25–28. So far, little is known about the role of prohibitin 2 in VSMC homeostasis.
Materials and Methods
Materials
Antibodies against COMP, TGN46, ERp5, SM22, calponin, ATP synthase subunit β, β-tubulin, α-actin and β-actin used for the western blot analysis, were purchased from Abcam (Cambridge, UK). Antibodies against GAPDH, His were obtained from Cell Signaling Technology (Boston, MA, USA). Antibodies against prohibitin 1, prohibitin 2 and eIF-5 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). IRDye-conjugated secondary antibodies for western blotting were purchased from Rockland, Inc. (Gilbertsville, PA, USA). JC-1, Mito-Tracker and antibody against COMP used for confocal fluorescence microscopy were purchased from Thermo Fisher Scientific (Thermo, NY, USA). Mito stress kit and cell energy phenotype kit were purchased from Agilent Seahorse XF Technology (Seahorse, CA, USA). PGC-1α plasmid was kindly provided by Prof. Changtao Jiang from Peking university. Other reagents were obtained from Sigma-Aldrich (St. Louis, MO, USA) unless specified.
Animal preparation
COMP−/− mice in the C57BL/6J background were kindly provided by Professor Äke Oldberg (Department of Cell and Molecular Biology, University of Lund, Sweden)29. Eight-week-old male and female COMP−/− mice and their wild-type (WT) littermates were used for VSMC isolation. All animal studies followed the guidelines of the Animal Care and Use Committee of Peking University.
Isolation of the mitochondrial fraction
Mitochondria were isolated by sucrose density gradient centrifugation according to a well-established protocol30. All steps were performed at 0–4 °C. Briefly, cells (5 × 107) were collected and washed twice with cold PBS. The cells were subsequently washed with 10 to 20 ml of TD buffer (134 mM NaCl, 5 mM KCl, 0.7 mM Na2HPO4, and 2.5 mM Tris, pH 7.5). Following centrifugation, the pellet was resuspended in 10 ml of MgRSB buffer (10 mM NaCl, 1.5 mM MgCl2, and 10 mM Tris, pH 7.5) and incubated for 10 min to swell. Swollen cells were collected in a glass homogenizer with 40 strokes, when ~70% of the cells were disrupted. To stabilize the mitochondria, 2.5× mannitol-sucrose buffer was added to a final concentration (210 mM mannitol, 70 mM sucrose, 5 mM Tris, and 5 mM EDTA, pH 7.5). Following the removal of the nuclei (3000 r.p.m., 10 min, 2 times), the mitochondria were pelleted from this supernatant at 15,000 r.p.m. for 20 min. Following resuspension in 5 ml of mannitol-sucrose buffer, the pellet was laid over a discontinuous sucrose gradient consisting of 15 ml of 1.0 M sucrose, 5 mM EDTA, and 10 mM Tris, pH 7.5, on top of 15 ml of 1.5 M sucrose, 5 mM EDTA, and 10 mM Tris, pH 7.5, and then was centrifuged at 4 °C for 30 min at 22,000 rpm. The components at the 1.0–1.5 M sucrose interface were collected as mitochondria.
Western blotting
Western blotting was performed as previously described31. Cells and mouse tissue extracts that contained equal amounts of total protein were resolved by 10 or 12% SDS-PAGE and were subsequently transferred onto nitrocellulose or PVDF membranes. The membranes were blocked with 5% milk in TBST, followed by incubation with primary antibody at 4 °C overnight. Following 1 h of incubation with IRDye-conjugated secondary antibodies (Rockland, Inc., Gilbertsville, PA, USA), the membranes were analyzed using an Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE, USA) to detect the immunofluorescence signal.
Mitochondrial subfractionation
Approximately 1 mg of mitochondria was sufficient for subfractionation as described32. All steps were performed at 0–4 °C. Briefly, mitochondria were suspended with 40 µl of T10E20 buffer (10 mM Tris-Cl, and 1 mM EDTA, pH 7.6) and were subsequently incubated with digitonin (0.1 mg digitonin/mg of mitochondrial protein). Three volumes of 250 mM sucrose in T10E20 buffer were added. Following centrifugation at 10,000 × g for 15 min, the inner mitochondrial membrane and matrix of the mitochondria were precipitated, whereas the outer membrane and intermembrane components were in the supernatant.
N-terminal sequencing
The mitochondrial and residual cytoplasmic fractions were isolated from HEK293A cells transfected with the full-length COMP plasmid as previously described, and the lysates were incubated with anti-COMP antibody. The precipitated proteins were denatured with 2× SDS sample buffer at 95 °C for 5 min and were subsequently loaded onto 8% gradient gels. Following coomassie brilliant blue staining, the protein bands present exclusively (110 kDa) were excised respectively. The N-terminus of each protein in the mitochondrial and non-mitochondrial cytoplasmic bands was labeled with a dimethyl moiety before mass spectrometric analysis, and each N-terminus of the trypsin post-digestive peptide fragment was sequenced for analysis.
Mitochondria transplantation
Mitochondria were transplanted as previously described33,34. To remove endogenous mitochondria, VSMCs at 80% confluence in culture were either maintained in DMEM as control or treated in DMEM supplemented with 110 µg/ml sodium pyruvate, 50 µg/ml uridine, and different concentrations of ethidium bromide (50, 100, or 200 ng/ml), respectively. After 2 weeks, mtDNA copy number was detected to verify removal efficiency. Then the VSMCs were incubated with 2.35 × 108/ml GFP-labeled exogenous mitochondria prepared from scrambled siRNA or COMP siRNA-transfected VSMCs at 37 °C for 24 h. The transplantation of exogenous mitochondria was evaluated and quantified by live cell imaging using mitochondria-targeted GFP as tracer. The oxygen consumption rate measurement was performed to detect the function of transplanted mitochondria.
Microarray analysis
Primary aortic VSMCs were isolated from WT and COMP−/− mice, and the mRNA was extracted from 5 × 106 cells isolated from 6 mice per sample using Trizol reagent (Invitrogen, CA, USA). The RNA quantity and quality were measured using a NanoDrop ND-1000 spectrophotometer, and the RNA integrity was assessed using standard denaturing agarose gel electrophoresis. The microarray experiments were performed using Kang Chen Bio-technology Corp (Shanghai, China) according to the standard protocol in three independent repeats. A Mouse DNA Array (Roche NimbleGen, Madison, WI, USA) was used to compare the gene expression between WT and COMP−/− VSMCs.
Briefly, the total RNA from each sample was used for labeling and array hybridization via the following steps: (1) reverse transcription using Invitrogen SuperScript ds-cDNA synthesis kit; (2) ds-cDNA labeling using the NimbleGen one-color DNA labeling kit; (3) array hybridization using the NimbleGen Hybridization System, followed by washing with the NimbleGen wash buffer kit; and (4) array scanning using the Axon GenePix 4000B microarray scanner (Molecular Devices Corporation). Scanned images (TIFFs) were subsequently imported into NimbleScan software (Version 2.5) for grid alignment and expression data analysis. The expression data were normalized using quantile normalization and the Robust Multichip Average (RMA) algorithm included in the NimbleScan software. All gene level files were imported into Agilent GeneSpring GX software (Version 11.5.1) for further analysis. Genes that were expressed at significantly different levels between the groups were identified through volcano plot filtering. Briefly, the p value of t test between the two groups were corrected by false discovery rate (FDR). Then a volcano plot was introduced to display log-fold-change against −log10(p value) from the t test. The cutoff of p value is 0.01. Differentially expressed genes were identified through fold change filtering (>2.0; <0.5). Pathway Analysis (KEGG) and GO analysis were used to analyze the functions of the differentially expressed genes.
Measurement of the mitochondrial oxygen consumption rate (OCR)
The OCRs were measured as previously described using an XF24 Extracellular Flux Analyzer (Seahorse Biosciences)35. Rat VSMCs were seeded in XF24 culture plates at a density of 20,000 cells per well overnight and were cultured with DMEM that contained 10% FBS. The direct measurement was recorded as the baseline OCR, followed by the addition of oligomycin (2 μM) to measure the ATP-linked OCR, and the oxidative phosphorylation uncoupler FCCP (2 μM) to indicate the maximal respiration. Finally, rotenone (1 μM) and antimycin A (1 μM) were injected to determine non-mitochondrial respiration. The operations followed the manufacturer’s protocol. The OCR was normalized by the amount in 100 μg of cellular protein in each well.
Recombinant adenovirus construction and infection
An adenovirus for full-length mouse COMP (Ad-COMP; NM_016685.2) was constructed and amplified according to the manufacturer’s protocol (BD Biosciences). An adenovirus that carried GFP (Ad-GFP) was used as a negative control. Cells cultured at ~80% confluence were infected with recombinant adenovirus (50 multiplicity of infection) for 48 h.
Plasmid construction and transfection
The cDNA fragment that encoded full-length rat prohibitin 2 (NCBI Reference sequence: NM_001013035.1) was cloned into the BamHI/XbaI sites of the pcDNA3.1 plasmid. The full-length COMP was subcloned into an C-terminal RFP vector for expression in primary mouse vascular smooth muscle cells. The full-length COMP coding sequence and fragments that encoded the 4 functional domains of mouse COMP (i.e., the N-terminus [N; aa 1–83], epidermal growth factor (EGF) repeat domain [EGF; aa 84–261], type III repeat domain [type III; aa 266–520], and C-terminus [C; aa 521–755]) were subcloned into an N-terminal FLAG vector for expression in COS-7 cells. The full-length prohibitin 2 coding sequence and fragments that encoded the 3 functional domains of mouse prohibitin 2 (i.e., the N-terminus [N; aa 1–39], prohibitin (PHB) domain [PHB; aa 34–264], and C-terminus [C; aa 201–299]) were subcloned into an N-terminal 6 × His vector for expression in HEK293A cells. In vitro plasmid transfection was performed using jetPEI (Polyplus-Transfection SA, Illkrich, France). The transfection procedures followed the manufacturers’ instructions and all the primers used for subcloning are shown in Supplemental Table III.
Rat carotid artery balloon injury
Male Sprague–Dawley rats (210–230 g) were used for the carotid artery injury model. All studies followed the guidelines of the Animal Care and Use Committee of Peking University. Briefly, rats were anesthetized by intraperitoneal injection of chloralhydrate (300 mg/kg). A 1.5-mm diameter balloon catheter (Medtronic, Minneapolis, Minn) was introduced through the left external carotid artery and distended then pulled back with constant rotation. This procedure was repeated for 5 times. Contralateral carotid arteries served as sham controls.
Recombinant adenovirus construction and infection in mice
The prohibitin 2 dominant-negative fragment (prohibitin 2-DN, aa201–299) was subcloned into an adenovirus vector pAdTrack-CMV. Subsequently, the recombinant adenovirus plasmids pDC316-mCMV-prohibitin 2-DN were transfected into HEK293A cells to yield the final expression clone Ad-prohibitin 2-DN. Ad-prohibitin 2-DN was amplified by infecting HEK293A cells and purified by PD-10 Sephadex (GE healthcare, Marlborough) precipitation. An adenovirus vector carrying green fluorescence protein (Ad-GFP) was applied as negative control. For in vivo studies, 1 × 1010 pfu of adenovirus dissolved in 30% pluronic gel solution were perivascularly delivered to the carotid arteries post balloon injury as described previously21.
Statistical analysis
All the results of the experimental studies are expressed as the mean ± SD. Statistical analysis was performed using GraphPad prism 6.0 software (GraphPad Software, San Diego, California, USA). Whether data are normally distributed was first evaluated. Then Brown-Forsythe test was performed for checking similar variances among normally distributed data followed by Student’s t test for two-group comparisons and ANOVA for more than two-group comparisons if evaluation of similar variances was passed. Nonparametric tests were used where data were not normally distributed. In all cases, statistical significance was concluded where the two-tailed probability was less than 0.05. Briefly, paired two-tailed Student’s t test was applied for the comparisons of the protein expression and mitochondrial membrane potential between the VSMCs transfected with scrambled siRNA and COMP siRNA, whereas unpaired two-tailed Student’s t-test was applied for the comparisons of the percentages of ATP production and amount of mtDNA between the VSMCs transfected with scrambled siRNA and COMP siRNA, as well as the comparisons of the mRNA levels between the WT and COMP−/− VSMCs, the comparation of neointima area, neointima/media ratio, circumference of EEL, the media area between Ad-GFP and Ad-prohibitin 2-DN infected rat carotid arteries. The comparisons of the protein expression among more than 2 groups by western blot were analyzed using one-way ANOVA followed by the Student–Newman–Keuls test for post-hoc comparison. The comparisons of the OCRs between the VSMCs treated with scrambled siRNA or COMP siRNA and control or COMP-deficient mitochondria as well as vector or prohibitin 2-DN plasmid were analyzed by unpaired two-tailed Student’s t test. Specific statistical analysis used in each experiment was described in detail in figure legends.
Results
COMP intracellularly localized in mitochondria
We previously showed that the ECM protein COMP is essential for maintaining the contractile phenotype of VSMCs, and siRNA-mediated silencing of COMP causes VSMC dedifferentiation20. Whether this is true in COMP−/− VSMCs was not explored. In the current study, we isolated primary VSMCs from COMP−/− and wild-type mice. COMP−/− VSMCs exhibited the decreased levels of contractile proteins, including α-actin, calponin and SM22 as well as morphological alteration to polygonal-shaped cells, which was rescued by the ectopic expression of COMP with red fluorescence protein labeled COMP (COMP-RFP) plasmid (Supplemental Figure IA-B). Intriguingly, we found an unexpected intracellular distribution of COMP-RFP in COMP−/− VSMCs (Supplemental Figure IC). To exclude the non-specific interference of COMP-RFP on COMP distribution, we subsequently performed dual immunofluorescence analysis to detect endogenous COMP expression in rat VSMCs. Surprisingly, COMP intracellularly localized and mainly resided in the mitochondria rather than the endoplasmic reticulum and Golgi complex, as evidenced by co-immunostaining of COMP with Mito-Tracker but not ERp5 or TGN46 in VSMCs (Fig. 1a). Moreover, we isolated mitochondrial and residual cytoplasmic fractions from rat and human VSMCs. Western blot analysis indicated that COMP existed in both the mitochondria and cytoplasm (Fig. 1b). Mitochondria have the following four compartments: the outer mitochondrial membrane (OMM), the intermembrane space (IMS), the inner mitochondrial membrane (IMM), and the mitochondrial matrix36. Upon further investigation of submitochondrial localization, we found that COMP preferentially localized in the IMM/matrix but was less abundant in the OMM/IMS (Fig. 1c). Together, the extracellular matrix protein COMP also localizes intracellularly in the mitochondria of VSMCs.
Most nuclear DNA coded mitochondrial proteins have amphiphilic N-terminal mitochondrial targeting sequence, which will be cut after translocated into mitochondria37. By using Mitofate (http://mitf.cbrc.jp/MitoFates/cgi-bin/top.cgi) software, the N-terminus (residues 12–23) of COMP is predicted to be responsible for mitochondrial targeting (data not shown). To investigate the definite sequence of mitochondrial COMP and cytoplasmic COMP, we subcloned the full-length of COMP and transfected it into HEK293A cells. Mitochondrial and mitochondria-free cytoplasmic fractions were isolated followed by immunoprecipitation. After Coomassie brilliant blue staining, the protein band of COMP (between 100 and 130 kDa) in each fraction was excised, and the N-terminus was labeled with a dimethyl moiety, followed by subjection to LC-MS/MS analysis (Supplemental Figure ID). Mascot reports revealed the same pre-labeled N-terminal peptide of COMP (15 aa, MS/MS spectrum shown in Fig. 1e) in mitochondria-free cytoplasmic and mitochondrial fractions. The N-termini of mitochondria-free cytoplasmic and mitochondrial COMP are both mapped from Gly21, suggesting that cytoplasmic and mitochondrial COMP share the same N-terminal signal peptide (aa 1–20) (Fig. 1d).
Mitochondrial COMP controls the contractile phenotype of VSMCs
To further investigate whether mitochondrial or non-mitochondrial COMP is responsible for VSMC identity, we performed mitochondrial transplantation as described previously33,34. The mitochondria were isolated from scrambled or COMP- silenced donor VSMCs and then transplanted into recipient mitochondria-deleted VSMCs treated with scrambled or COMP siRNA respectively (Fig. 2a). The efficiency of mitochondrial deletion after ethidium bromide stimulation and mitochondria transplantation was examined by mtDNA level and live-cell confocal imaging respectively (Fig. 2b,c). Oxygen consumption rate of post-transplanted VSMCs measured using the Seahorse XF24 flux analyzer was performed to determine the function of transplanted mitochondria (data not shown). Both mitochondrial-deficiency and non-mitochondrial-deficiency of COMP contributed to VSMC dedifferentiation, whereas dual deficiency of COMP caused more significant alteration. Even though COMP in the mitochondrial fraction was minor compared to the mito-free cytosolic fraction (Fig. 1b and Supplemental Figure ID), our data suggested that mitochondria-resident COMP also contributed to VSMC contractile phenotype maintenance (Fig. 2d).
COMP−/− VSMCs exhibit dysfunction of mitochondrial oxidative phosphorylation
Previously, we have shown that extracellular COMP binds to integrin α7β1 to maintain the contractile phenotype of VSMCs20. To further assess how intracellular COMP regulates this process, we performed gene-expression microarray analysis between primary WT and COMP−/− VSMCs. Overall, 7237 genes were upregulated, whereas 6389 genes were downregulated by COMP deficiency. GO and KEGG analysis revealed that those genes regulated by COMP deficiency were involved in multiple pathways, including metabolic processes, cell binding and oxidative phosphorylation (Supplemental Figure II). Intriguingly, among these pathways, the genes related to mitochondrial oxidative phosphorylation were most significantly downregulated in response to COMP deficiency (Fig. 3a, b). To validate the array data, we performed RT-qPCR analysis in primary WT and COMP−/− VSMCs regarding the genes related to the activity of mitochondrial respiratory chain complexes and oxidative phosphorylation (ATP 5d, ATP 5k, Cox 5a, Cox 5b, Cox 8b, Ndufa 5, Ndufa 9 and Ndufa 11). Similar results were obtained (Fig. 3c). To determine whether COMP deficiency truly affects mitochondrial oxidative phosphorylation, we subsequently measured the oxygen consumption rate (OCR) between the VSMCs transfected with scrambled or COMP siRNA using an XF24 flux analyzer. The measurement was performed by sequential injection of the ATP synthase inhibitor oligomycin, uncoupler FCCP, and the combination of the electron transport chain inhibitors rotenone and antimycin A. Both the basal mitochondrial respiration and the maximal respiratory capacity were attenuated in the COMP-silenced VSMCs compared with the scrambled siRNA-transfected VSMCs. Moreover, oligomycin caused less reduction of the mitochondrial OCR in the COMP-silenced VSMCs than in the scrambled control cells, indicating that ATP synthesis-linked OCR was attenuated by COMP deficiency (Fig. 3d). Consistently, ATP production was significantly decreased in the COMP-silenced VSMCs compared with the control VSMCs (Fig. 3e). We further investigated whether deficiency of mitochondrial or non-mitochondrial cytoplasmic COMP is responsible for ATP production. After mitochondria transplantation, we found that deficiency of mitochondrial-resident COMP, but not non-mitochondrial COMP, was responsible for ATP production (Fig. 3f, g). In accordance, COMP deficiency in mitochondria caused decreased mitochondrial respiration. These findings indicate that COMP deficiency disrupted mitochondrial bioenergetics in VSMCs.
COMP deficiency causes mitochondrial dysfunction
Impaired oxidative phosphorylation has been proposed as a primary factor initiating mitochondrial dysfunction, which is characterized by decreased mitochondrial membrane potential (ΔΨm), reduced mitochondrial DNA (mtDNA) number, reduced autophagic flux and mitochondrial morphological changes. We firstly measured the mitochondrial membrane potential (△Ψm) using JC-1 dye staining. COMP silencing consistently decreased the intracellular red fluorescence signaling but enhanced green fluorescence signaling in the VSMCs, suggesting that △Ψm was significantly attenuated in the COMP-silenced VSMCs (Fig. 4a). Additionally, mitochondrial-resident COMP knockdown attenuated the mitochondrial membrane potential (Fig. 4b). Moreover, the relative content of mitochondrial DNA (mtDNA) was significantly reduced in COMP-silenced VSMCs (Fig. 4c).
Mitochondria have been recognized as highly dynamic and constantly undergo fission (the production of short mitochondrial rods or spheres) and fusion (the promotion of a long, filamentous morphology of mitochondria), which maintains mitochondrial homeostasis38. Decreased fusion or increased fission results in mitochondrial fragmentation, an increase in the number of abnormal mitochondria and VSMC proliferation39. COMP-silenced VSMCs exhibited substantial mitochondrial fragmentation, as indicated by Mito-Tracker staining (Fig. 4d).
Together, the data showed that COMP deficiency impaired mitochondrial oxidative phosphorylation and caused mitochondrial dysfunction.
Mitochondrial bioenergetics defects by COMP deficiency contributes to VSMC dedifferentiation
Although accumulating studies have suggested the altered mitochondrial metabolism among different differentiation state of aortic SMCs, there is no direct evidence showing the cause-effect relationship12. We first examined the cell energy phenotype and mitochondrial respiration rate of VSMCs under different differentiation states upon PDGF-BB or TGF-β stimulation. PDGF-BB-induced VSMC dedifferentiation paralleled with decreased respiration, whereas the TGF-β-driven contractile phenotype of VSMCs exhibited enhanced mitochondrial respiration (Fig. 5a, b, Supplemental Figure III). We next asked whether the interruption of the oxidative phosphorylation affects the phenotype of VSMCs. Oligomycin is a well-known inhibitor of mitochondrial ATP synthase and oxidative phosphorylation40. Interestingly, our data showed oligomycin could cause contractile VSMC dedifferentiation upon serum starvation (Fig. 5c). PGC-1α, a master regulator of mitochondrial biogenesis, upregulates mitochondrial oxidative phosphorylation-related genes and inhibits neointima formation after vascular injury in rats41. Similarly, western blotting showed that PGC-1α promoted contractile phenotype of VSMCs (Fig. 5d).
We then asked whether COMP regulates the VSMC phenotype via modulation of mitochondrial respiration. Intriguingly, COMP overexpression by adenovirus no longer maintained the contractile phenotype of VSMCs when mitochondrial respiration was inhibited by oligomycin (Fig. 5e). Thus, COMP-regulated VSMC phenotype, at least in part, is attributed to mitochondrial respiration.
Mitochondrial proteomics identifies prohibitin 2 as a binding partner of COMP
To further explore the mechanism underlying COMP regulation on mitochondrial function, we performed mitochondrial proteomics using COMP adenovirus-infected VSMCs. Seven protein bands that specifically immunoprecipitated by COMP antibody but not control IgG were excised and subjected to LC-MS/MS analysis (Fig. 6a). Thus, 602 proteins were identified. Through further DAVID Database analysis, 19 known mitochondria-resident proteins were selected as potential COMP-binding proteins in the mitochondria of VSMCs (Supplemental Table I). Among these proteins, we screened the top-two potential COMP-interacting proteins which have been reported to be involved in the regulation of oxidative phosphorylation (ATP synthase subunit β and prohibitin 2). We initially detected ATP synthase subunit β, the key catalytic subunit of mitochondrial F1Fo-ATP synthase, for ATP synthesis42. However, ATP synthase subunit β did not co-immunoprecipitate with COMP in VSMCs whereas ATP synthase subunit β was detected in mitochondrial (Supplemental Figure IVA). Next, we tested the potential interaction between COMP and prohibitin 2. The loss of prohibitin 2 impairs respiratory supercomplex formation and causes defects in the mitochondrial respiratory capacity, membrane potential and mitochondrial morphology43,44. Through co-immunoprecipitation analysis of the mitochondrial fraction of VSMCs, prohibitin 2 was immunoprecipitated by anti-COMP antibody but not by control IgG (Fig. 6b). Notably, COMP was also exclusively immunoprecipitated by anti-prohibitin 2 antibody (Fig. 6c). In accordance, COMP and prohibitin 2 colocalized in VSMCs as observed under immunofluorescence confocal microscopy (Supplemental Figure IVB). Since prohibitin 1 and prohibitin 2 could form a complex to regulate mitochondrial function45,46, we also studied the possible interaction of prohibitin 1 and COMP and found that COMP also immunoprecipitated with prohibitin 1 (Supplemental Figure IVC). To further verify the interaction and identify the specific binding motif of COMP, we subcloned full-length COMP and various domains of COMP (i.e., the N-terminus [N; aa 1–83], epidermal growth factor (EGF) repeat domain [EGF; aa 84–261], type III repeat domain [type III; aa 266–520], and C-terminus [C; aa 521–755]) into the flag-CMV plasmids. COS-7 cells were transfected with the pcDNA3.1-prohibitin 2 plasmid and flag-CMV plasmids that flanked the COMP full length/fragments individually, followed by co-immunoprecipitation using anti-flag antibodies. Both the flag-COMP and flag-EGF domain, but not the other domains, specifically immunoprecipitated prohibitin 2 via flag antibodies but not by IgG (Fig. 6d). Next, we subcloned different domains of prohibitin 2 (i.e., the N-terminus [N; aa 1–39], prohibitin domain [PHB; aa 34–264], and C-terminus [C; aa 201–299]) into the 6 × His-pcDNA3.1 plasmid. HEK293A cells were transfected with full-length flag-COMP and the 6 × His-pcDNA3.1 plasmid that flanked the prohibitin 2 fragments individually, followed by co-immunoprecipitation using anti-Flag antibody. Flag-COMP specifically immunoprecipitated the 6 × His-C terminal domain of prohibitin 2 via Flag antibody but not via the control IgG (Fig. 6e). Taken together, the data revealed that prohibitin 2 directly interacts with COMP at the EGF domain via its C-terminus.
COMP–prohibitin 2 interaction maintains mitochondrial homeostasis and the VSMC contractile phenotype
To further explore the COMP–prohibitin 2 interaction in the modulation of mitochondrial respiration and VSMC differentiation, the plasmid encoding the C-terminus of prohibitin 2 was transfected into VSMCs as a dominant-negative (DN) domain to block the binding between COMP and prohibitin 2 (Supplemental Figure VA). Consequently, transfection of the DN domain into contractile VSMCs markedly inhibited mitochondrial respiration, ATP production, and the membrane potential, greatly mimicking COMP-deficient VSMCs. Meanwhile, VSMCs underwent phenotype transition toward dedifferentiation (Fig. 7a–d). In addition, adenovirus-mediated overexpression of the DN domain in carotid arteries significantly aggravated balloon injury-induced neointima formation (11.14 ± 1.19 vs. 18.62 ± 0.96 × 104 µm2) in rats (Fig. 7e and Supplemental Figure VB), indicating that disruption of the COMP–prohibitin 2 interaction led to VSMC dedifferentiation and intimal hyperplasia in vivo. Thus, the COMP–prohibitin 2 interaction plays an essential role in maintaining mitochondrial homeostasis and the VSMC contractile phenotype.
Discussion
Understanding the molecular mechanisms regulating SMC phenotype transition is critical to elucidating a novel therapeutics for cardiovascular diseases. In the current study, we revealed a pivotal role of the intracellular COMP–prohibitin 2 interaction in maintaining mitochondrial homeostasis and the contractile phenotype of VSMCs. Our data particularly highlight the importance of mitochondrial respiration regulated by COMP–prohibitin 2 in VSMC phenotypic modulation and may shed light on the development of a novel therapeutic strategy.
Mitochondria not only are the powerhouses for ATP production but also play critical roles in ROS generation, inflammation, metabolism and apoptosis47,48. Accumulating evidence has linked vascular diseases such as atherosclerosis and pulmonary hypertension to increased mitochondria-generated ROS, accumulation of mitochondrial DNA (mtDNA) damage and progressive respiratory chain dysfunction49,50. However, the molecular link of mitochondrial dysfunction to vascular diseases is not fully understood. We previously identified COMP as an important modulator in maintaining vascular homeostasis. COMP−/− mice are more susceptible to post-injury restenosis, atherosclerosis, vascular calcification and thrombosis formation20,21,51,52. COMP-degrading proteinase ADAMTS-7 has been demonstrated to be involved in the pathogenesis of atherosclerosis by both human genome-wide association studies and in vivo mouse models31,53. Herein, we revealed an unexpected intracellular distribution of COMP and its undisputable role in the maintenance of mitochondrial homeostasis in VSMCs. COMP deficiency led to impaired mitochondrial respiration and ATP production and systemic mitochondrial dysfunction, which may also be involved in the aberrant vascular phenotype in COMP−/− mice.
Of interest, our proteomics analysis identified a mitochondrial binding partner of COMP, prohibitin 2. COMP deficiency shares similar identities with prohibitin 2 deficiency in mitochondrial dysfunction, as previous studies revealed that lack of prohibitin 2 impaired oxidative phosphorylation, reduced mtDNA copy number and attenuated mitochondrial membrane potential25,54. In addition, Prohibitin 2 deficiency inhibits the activities of complex I, II and IV in mitochondrial respiratory chain25. Although the mRNA levels of mitochondrial respiration complex subunits (ATP5b, Cox5a, Ndufa5 etc.) were significantly dowregulated by COMP deficiency, whether COMP regulates mitochondrial respiration complex activity needs to be further studied. Prohibitin 2 is also associated with many critical mitochondrial proteins, including components of the mitochondrial respiratory chain, mitochondrial structure and cristae formation, mitochondrial transporters, membrane translocases, mitochondrial-mediated translation, and mitochondrial apoptosis55,56. A recent study also revealed prohibitin 2 as an inner membrane mitophagy receptor57. In the current study, we found that COMP and prohibitin 2 are functionally interdependent in the regulation of mitochondrial respiration via direct interaction. Whether the COMP–prohibitin 2 interaction affects other mitochondrial structures and functions needs to be further explored. In addition, prohibitin 2 is ubiquitously expressed in many other tissues, such as the heart58. The mitochondrial COMP–prohibitin 2 interaction may not be limited to VSMCs. We did observe COMP expressed in the mitochondria in cardiomyocytes (data not shown), and COMP deficiency caused spontaneous dilated cardiomyopathy59. Whether the COMP–prohibitin 2 interaction in the heart plays essential roles in mitochondrial function and heart failure requires further investigation.
Another interesting finding of our study is that mitochondrial bioenergetics regulated by COMP–prohibitin 2 directs VSMC phenotypic transition. Until recently, little has been known regarding mitochondrial respiration in terms of VSMC function. Interestingly, direct measurement of the cellular bioenergetics of human coronary artery smooth muscle revealed that VSMCs appear to be very similar to cardiac and skeletal muscle cells in terms of oxidative phosphorylation capacity, although VSMCs have a lower mitochondrial content11. Aging cells or PDGF-BB-treated dedifferentiated VSMCs have lower oxidative phosphorylation and reduced reserve capacity18. Moreover, a metabolic shift from oxidative phosphorylation to glycolysis and substrate selectivity between glucose and fat oxidation were observed in synthetic VSMCs12,60. Recent research reported lactate could promote synthetic phenotype in VSMCs61.This process was similar to the Warburg effect present in cancer cells that is known to favor glycolysis even when well oxygenated. Our study not only provides further direct evidence that the manipulation of mitochondrial respiration led to VSMC phenotypic transition but also reveals maintaining mitochondrial respiration may inhibit VSMC phenotype switching and alleviate vascular diseases. However, how the alteration of mitochondrial metabolism contributes to the VSMC phenotypic transition needs further investigation.
A surprising finding in this study is the localization of the ECM protein COMP in the mitochondria. COMP belongs to the thrombospondins (TSP) family and is also referred to as TSP-5. Accumulating evidence has indicated that COMP, as an extracellular protein, exerts its functions in both the musculoskeletal and cardiovascular systems by binding to other ECM proteins (e.g., matrilin, fibronectin, and collagen), mitogens (e.g., TGF-β and BMP-2), membrane proteins (e.g., integrin β1 and β3) or thrombin21,51,52,59,62–64. To the best of our knowledge, this is the first study to demonstrate that COMP intracellularly resides in an organelle and plays a role in mitochondrial function under physiological conditions. Previously, mutations in the human COMP gene have been linked to the development of two inherited chondrodysplasia and osteoarthritic phenotype, pseudoachondroplasia and multiple epithelial dysplasia, because of aberrant COMP retention in the ER and subsequent ER stress62. Of interest, TSP-4, which is also a thrombospondin family member, has been reported as an intracellular adaptive ER stress response effector via binding with the ER luminal domain of activating transcription factor 6a (ATF6a)65. More intriguingly, MMP-12, an extracellular matrix metalloproteinase, is transported into virus-infected cells and further translocated into the nucleus, where it acts as a transcription factor66. The notion that the same protein with different subcellular localizations plays various roles in cell behavior highlights the complexities of the ECM superfamily proteins.
Our previous study showed the COMP is unregulated by serum starving or TGF-β and repressed by PDGF-BB or serum supplement in VSMCs during phenotype switching20. Moreover, we also identified COMP degradation by metalloproteinase ADAMTS-7 during vascular injury or calcification31,67. How mitochondrial COMP level was regulated needs further exploration.
Thus, COMP deficiency aggravates VSMC phenotypic switching, at least in part, by disrupting mitochondrial homeostasis maintained by the interaction between COMP and prohibitin 2. Increasing endogenous COMP or improving mitochondrial respiration may help maintain the VSMC contractile phenotype to inhibit several cardiovascular diseases.
Electronic supplementary material
Acknowledgements
This research was supported by funding from the National Natural Science Foundation of the People's Republic of China (91539203, 81730010); the National Key R&D Program of China (2016YFC0903000); the International Cooperation and Exchanges NSFC (81220108004); the 111 Project of Chinese Ministry of Education (B07001).
Conflict of interest
The authors declare that they have no conflict of interest.
Footnotes
These authors contributed equally: Yiting Jia, Meili Wang
Edited by C. Munoz-Pinedo
Electronic supplementary material
Supplementary Information accompanies this paper at (10.1038/s41419-018-0703-x).
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 2004;84:767–801. doi: 10.1152/physrev.00041.2003. [DOI] [PubMed] [Google Scholar]
- 2.Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. Circ. Res. 2016;118:692–702. doi: 10.1161/CIRCRESAHA.115.306361. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Leopold JA. Vascular calcification: Mechanisms of vascular smooth muscle cell calcification. Trends Cardiovasc. Med. 2015;25:267–274. doi: 10.1016/j.tcm.2014.10.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Starke RM, et al. Vascular smooth muscle cells in cerebral aneurysm pathogenesis. Transl. Stroke Res. 2014;5:338–346. doi: 10.1007/s12975-013-0290-1. [DOI] [PubMed] [Google Scholar]
- 5.Shi N, Chen SY. Mechanisms simultaneously regulate smooth muscle proliferation and differentiation. J. Biomed. Res. 2014;28:40–46. doi: 10.7555/JBR.28.20130130. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem. Pharmacol. 2009;78:539–552. doi: 10.1016/j.bcp.2009.04.029. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Clempus RE, et al. Nox4 is required for maintenance of the differentiated vascular smooth muscle cell phenotype. Arterioscler. Thromb. Vasc. Biol. 2007;27:42–48. doi: 10.1161/01.ATV.0000251500.94478.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Revuelta-Lopez E, et al. Hypoxia induces metalloproteinase-9 activation and human vascular smooth muscle cell migration through low-density lipoprotein receptor-related protein 1-mediated Pyk2 phosphorylation. Arterioscler. Thromb. Vasc. Biol. 2013;33:2877–2887. doi: 10.1161/ATVBAHA.113.302323. [DOI] [PubMed] [Google Scholar]
- 9.Halka AT, et al. The effects of stretch on vascular smooth muscle cell phenotype in vitro. Cardiovasc. Pathol. 2008;17:98–102. doi: 10.1016/j.carpath.2007.03.001. [DOI] [PubMed] [Google Scholar]
- 10.Doi H, et al. HERP1 inhibits myocardin-induced vascular smooth muscle cell differentiation by interfering with SRF binding to CArG box. Arterioscler. Thromb. Vasc. Biol. 2005;25:2328–2334. doi: 10.1161/01.ATV.0000185829.47163.32. [DOI] [PubMed] [Google Scholar]
- 11.Park SY, et al. Cardiac, skeletal, and smooth muscle mitochondrial respiration: are all mitochondria created equal? Am. J. Physiol. Heart Circ. Physiol. 2014;307:H346–H352. doi: 10.1152/ajpheart.00227.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Werle M, et al. Metabolic control analysis of the Warburg-effect in proliferating vascular smooth muscle cells. J. Biomed. Sci. 2005;12:827–834. doi: 10.1007/s11373-005-9010-5. [DOI] [PubMed] [Google Scholar]
- 13.Mercer JR. Mitochondrial bioenergetics and therapeutic intervention in cardiovascular disease. Pharmacol. Ther. 2014;141:13–20. doi: 10.1016/j.pharmthera.2013.07.011. [DOI] [PubMed] [Google Scholar]
- 14.Madamanchi NR, Runge MS. Mitochondrial dysfunction in atherosclerosis. Circ. Res. 2007;100:460–473. doi: 10.1161/01.RES.0000258450.44413.96. [DOI] [PubMed] [Google Scholar]
- 15.Li H, Horke S, Forstermann U. Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis. 2014;237:208–219. doi: 10.1016/j.atherosclerosis.2014.09.001. [DOI] [PubMed] [Google Scholar]
- 16.Vasquez-Trincado C, et al. Mitochondrial dynamics, mitophagy and cardiovascular disease. J. Physiol. 2016;594:509–525. doi: 10.1113/JP271301. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Yu E, Mercer J, Bennett M. Mitochondria in vascular disease. Cardiovasc. Res. 2012;95:173–182. doi: 10.1093/cvr/cvs111. [DOI] [PubMed] [Google Scholar]
- 18.Salabei JK, Hill BG. Mitochondrial fission induced by platelet-derived growth factor regulates vascular smooth muscle cell bioenergetics and cell proliferation. Redox Biol. 2013;1:542–551. doi: 10.1016/j.redox.2013.10.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Rafikov R, et al. Complex I dysfunction underlies the glycolytic switch in pulmonary hypertensive smooth muscle cells. Redox Biol. 2015;6:278–286. doi: 10.1016/j.redox.2015.07.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Wang L, et al. Cartilage oligomeric matrix protein maintains the contractile phenotype of vascular smooth muscle cells by interacting with alpha(7)beta(1) integrin. Circ. Res. 2010;106:514–525. doi: 10.1161/CIRCRESAHA.109.202762. [DOI] [PubMed] [Google Scholar]
- 21.Du Y, et al. Cartilage oligomeric matrix protein inhibits vascular smooth muscle calcification by interacting with bone morphogenetic protein-2. Circ. Res. 2011;108:917–928. doi: 10.1161/CIRCRESAHA.110.234328. [DOI] [PubMed] [Google Scholar]
- 22.Fu Y, et al. Shift of macrophage phenotype due to cartilage oligomeric matrix protein deficiency drives atherosclerotic calcification. Circ. Res. 2016;119:261–276. doi: 10.1161/CIRCRESAHA.115.308021. [DOI] [PubMed] [Google Scholar]
- 23.Kim JW, et al. Activation of an estrogen/estrogen receptor signaling by BIG3 through its inhibitory effect on nuclear transport of PHB2/REA in breast cancer. Cancer Sci. 2009;100:1468–1478. doi: 10.1111/j.1349-7006.2009.01209.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Coates PJ, et al. Mammalian prohibitin proteins respond to mitochondrial stress and decrease during cellular senescence. Exp. Cell Res. 2001;265:262–273. doi: 10.1006/excr.2001.5166. [DOI] [PubMed] [Google Scholar]
- 25.Strub GM, et al. Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration. FASEB J. 2011;25:600–612. doi: 10.1096/fj.10-167502. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Back JW, et al. A structure for the yeast prohibitin complex: Structure prediction and evidence from chemical crosslinking and mass spectrometry. Protein Sci. 2002;11:2471–2478. doi: 10.1110/ps.0212602. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Bogenhagen DF, Wang Y, Shen EL, Kobayashi R. Protein components of mitochondrial DNA nucleoids in higher eukaryotes. Mol. Cell. Proteom. 2003;2:1205–1216. doi: 10.1074/mcp.M300035-MCP200. [DOI] [PubMed] [Google Scholar]
- 28.Hoppins S, Lackner L, Nunnari J. The machines that divide and fuse mitochondria. Annu. Rev. Biochem. 2007;76:751–780. doi: 10.1146/annurev.biochem.76.071905.090048. [DOI] [PubMed] [Google Scholar]
- 29.Svensson L, et al. Cartilage oligomeric matrix protein-deficient mice have normal skeletal development. Mol. Cell. Biol. 2002;22:4366–4371. doi: 10.1128/MCB.22.12.4366-4371.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Bogenhagen D, Clayton DA. The number of mitochondrial deoxyribonucleic acid genomes in mouse L and human HeLa cells. Quantitative isolation of mitochondrial deoxyribonucleic acid. J. Biol. Chem. 1974;249:7991–7995. [PubMed] [Google Scholar]
- 31.Wang L, et al. ADAMTS-7 mediates vascular smooth muscle cell migration and neointima formation in balloon-injured rat arteries. Circ. Res. 2009;104:688–698. doi: 10.1161/CIRCRESAHA.108.188425. [DOI] [PubMed] [Google Scholar]
- 32.Pallotti F, Lenaz G. Isolation and subfractionation of mitochondria from animal cells and tissue culture lines. Methods Cell Biol. 2007;80:3–44. doi: 10.1016/S0091-679X(06)80001-4. [DOI] [PubMed] [Google Scholar]
- 33.Zhou J, et al. Mitochondrial transplantation attenuates hypoxic pulmonary vasoconstriction. Oncotarget. 2016;7:31284–31298. doi: 10.18632/oncotarget.8893. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Zhu L, et al. Mitochondrial transplantation attenuates hypoxic pulmonary hypertension. Oncotarget. 2016;7:48925–48940. doi: 10.18632/oncotarget.10596. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Kalghatgi S, et al. Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in Mammalian cells. Sci. Transl. Med. 2013;5:192ra185. doi: 10.1126/scitranslmed.3006055. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Scheffler NK, et al. Two-dimensional electrophoresis and mass spectrometric identification of mitochondrial proteins from an SH-SY5Y neuroblastoma cell line. Mitochondrion. 2001;1:161–179. doi: 10.1016/S1567-7249(01)00007-1. [DOI] [PubMed] [Google Scholar]
- 37.Kunze M, Berger J. The similarity between N-terminal targeting signals for protein import into different organelles and its evolutionary relevance. Front. Physiol. 2015;6:259. doi: 10.3389/fphys.2015.00259. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. Science. 2012;337:1062–1065. doi: 10.1126/science.1219855. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Ni HM, Williams JA, Ding WX. Mitochondrial dynamics and mitochondrial quality control. Redox Biol. 2015;4:6–13. doi: 10.1016/j.redox.2014.11.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Devenish RJ, Prescott M, Boyle GM, Nagley P. The oligomycin axis of mitochondrial ATP synthase: OSCP and the proton channel. J. Bioenerg. Biomembr. 2000;32:507–515. doi: 10.1023/A:1005621125812. [DOI] [PubMed] [Google Scholar]
- 41.Qu A, et al. PGC-1alpha attenuates neointimal formation via inhibition of vascular smooth muscle cell migration in the injured rat carotid artery. Am. J. Physiol. Cell Physiol. 2009;297:C645–C653. doi: 10.1152/ajpcell.00469.2008. [DOI] [PubMed] [Google Scholar]
- 42.Hubbard MJ, McHugh NJ. Mitochondrial ATP synthase F1-beta-subunit is a calcium-binding protein. FEBS Lett. 1996;391:323–329. doi: 10.1016/0014-5793(96)00767-3. [DOI] [PubMed] [Google Scholar]
- 43.Artal-Sanz M, Tavernarakis N. Prohibitin and mitochondrial biology. Trends Endocrinol. Metab. 2009;20:394–401. doi: 10.1016/j.tem.2009.04.004. [DOI] [PubMed] [Google Scholar]
- 44.Korwitz A, et al. Loss of OMA1 delays neurodegeneration by preventing stress-induced OPA1 processing in mitochondria. J. Cell. Biol. 2016;212:157–166. doi: 10.1083/jcb.201507022. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Osman C, Merkwirth C, Langer T. Prohibitins and the functional compartmentalization of mitochondrial membranes. J. Cell. Sci. 2009;122:3823–3830. doi: 10.1242/jcs.037655. [DOI] [PubMed] [Google Scholar]
- 46.Merkwirth C, Langer T. Prohibitin function within mitochondria: essential roles for cell proliferation and cristae morphogenesis. Biochim. Biophys. Acta. 2009;1793:27–32. doi: 10.1016/j.bbamcr.2008.05.013. [DOI] [PubMed] [Google Scholar]
- 47.Estaquier J, Vallette F, Vayssiere JL, Mignotte B. The mitochondrial pathways of apoptosis. Adv. Exp. Med. Biol. 2012;942:157–183. doi: 10.1007/978-94-007-2869-1_7. [DOI] [PubMed] [Google Scholar]
- 48.Richter-Dennerlein R, Dennerlein S, Rehling P. Integrating mitochondrial translation into the cellular context. Nat. Rev. Mol. Cell Biol. 2015;16:586–592. doi: 10.1038/nrm4051. [DOI] [PubMed] [Google Scholar]
- 49.Yu EP, Bennett MR. Mitochondrial DNA damage and atherosclerosis. Trends Endocrinol. Metab. 2014;25:481–487. doi: 10.1016/j.tem.2014.06.008. [DOI] [PubMed] [Google Scholar]
- 50.Belostotsky R, et al. Mutations in the mitochondrial seryl-tRNA synthetase cause hyperuricemia, pulmonary hypertension, renal failure in infancy and alkalosis, HUPRA syndrome. Am. J. Hum. Genet. 2011;88:193–200. doi: 10.1016/j.ajhg.2010.12.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Acharya C, et al. Cartilage oligomeric matrix protein and its binding partners in the cartilage extracellular matrix: interaction, regulation and role in chondrogenesis. Matrix Biol. 2014;37:102–111. doi: 10.1016/j.matbio.2014.06.001. [DOI] [PubMed] [Google Scholar]
- 52.Liang Y, et al. Cartilage oligomeric matrix protein is a natural inhibitor of thrombin. Blood. 2015;126:905–914. doi: 10.1182/blood-2015-01-621292. [DOI] [PubMed] [Google Scholar]
- 53.Reilly MP, et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet. 2011;377:383–392. doi: 10.1016/S0140-6736(10)61996-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Merkwirth C, et al. Loss of prohibitin membrane scaffolds impairs mitochondrial architecture and leads to tau hyperphosphorylation and neurodegeneration. PLoS Genet. 2012;8:e1003021. doi: 10.1371/journal.pgen.1003021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Bavelloni A, Piazzi M, Raffini M, Faenza I, Blalock WL. Prohibitin 2: At a communications crossroads. IUBMB Life. 2015;67:239–254. doi: 10.1002/iub.1366. [DOI] [PubMed] [Google Scholar]
- 56.Merkwirth C, et al. Prohibitins control cell proliferation and apoptosis by regulating OPA1-dependent cristae morphogenesis in mitochondria. Genes Dev. 2008;22:476–488. doi: 10.1101/gad.460708. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Wei Y, Chiang WC, Sumpter R, Jr., Mishra P, Levine B. Prohibitin 2 Is an inner mitochondrial membrane mitophagy receptor. Cell. 2017;168:224–238. doi: 10.1016/j.cell.2016.11.042. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Muraguchi T, Kawawa A, Kubota S. Prohibitin protects against hypoxia-induced H9c2 cardiomyocyte cell death. Biomed. Res. 2010;31:113–122. doi: 10.2220/biomedres.31.113. [DOI] [PubMed] [Google Scholar]
- 59.Huang Y, et al. Deficiency of cartilage oligomeric matrix protein causes dilated cardiomyopathy. Basic Res. Cardiol. 2013;108:374. doi: 10.1007/s00395-013-0374-9. [DOI] [PubMed] [Google Scholar]
- 60.Chiong M, et al. Influence of glucose metabolism on vascular smooth muscle cell proliferation. Vasa. 2013;42:8–16. doi: 10.1024/0301-1526/a000243. [DOI] [PubMed] [Google Scholar]
- 61.Yang L, et al. Lactate promotes synthetic phenotype in vascular smooth muscle cells. Circ. Res. 2017;121:1251–1262. doi: 10.1161/CIRCRESAHA.117.311819. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Posey KL, Hayes E, Haynes R, Hecht JT. Role of TSP-5/COMP in pseudoachondroplasia. Int. J. Biochem. Cell. Biol. 2004;36:1005–1012. doi: 10.1016/j.biocel.2004.01.011. [DOI] [PubMed] [Google Scholar]
- 63.Fu, Y. et al. Shift of macrophage phenotype due to cartilage oligomeric matrix protein deficiency drives atherosclerotic calcification. Circ Res.10.1161/CIRCRESAHA.115.308021 (2016). [DOI] [PubMed]
- 64.Fu, Y., Wang, X. & Kong, W. Hyperhomocysteinaemia and vascular injury: advances in mechanisms and drug targets. Br J. Pharmacol. 10.1111/bph.13988 (2017). [DOI] [PMC free article] [PubMed]
- 65.Lynch JM, et al. A thrombospondin-dependent pathway for a protective ER stress response. Cell. 2012;149:1257–1268. doi: 10.1016/j.cell.2012.03.050. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Marchant DJ, et al. A new transcriptional role for matrix metalloproteinase-12 in antiviral immunity. Nat. Med. 2014;20:493–502. doi: 10.1038/nm.3508. [DOI] [PubMed] [Google Scholar]
- 67.Du Y, et al. Upregulation of a disintegrin and metalloproteinase with thrombospondin motifs-7 by miR-29 repression mediates vascular smooth muscle calcification. Arterioscler. Thromb. Vasc. Biol. 2012;32:2580–2588. doi: 10.1161/ATVBAHA.112.300206. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.